Alembic obtains FDA nod for generic Firazyr
Generic Firazyr is used for the treatment of acute attacks of hereditary angioedema in adults 18 years of age and older.
Alembic has received the Food and Drug Administration’s blessing for Icatibant Injection, 30 mg/3 ml (10 mg/ml) Single-Dose Prefilled Syringe, which is the generic of Takeda’s Firazyr.
The medication is used for the treatment of acute attacks of hereditary angioedema in adults 18 years of age and older.
[Read more: Alembic intros generic Perforomist]
This is the first peptide product approval from the FDA received by the company.
Icatibant Injection has a market value of $112 million for the 12 months ending March 2024, per IQVIA.
[Read more: Alembic intros generic Enablex]